Navigation Links
Consumer Reports' Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
Date:9/5/2007

Caution Urged In Use of Anticonvulsants, Especially When Prescribed 'Off-Label'

WASHINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Some anticonvulsant drugs are effective in treating bipolar disorder, fibromyalgia, and various kinds of pain, but the widely prescribed drugs are not always the best initial choice to treat those conditions and some of the drugs are quite expensive, according to the latest report from Consumer Reports Best Buy Drugs(TM), a public information project of Consumers Union.

The report -- written for consumers and available free at http://www.CRBestBuyDrugs.org -- compares and analyzes 12 anticonvulsants. Scientific evidence backs only a few in treating the three disorders. That is significant because many of the 12 drugs are commonly prescribed "off label" to treat mental health and pain problems.

"This is a case where a class of drugs is widely used off-label to treat millions of Americans with assorted types of pain, emotional distress, and mental health problems," says Gail Shearer, project director of Consumer Reports Best Buy Drugs. "But the evidence is either weak or non-existent that some of them help people or are the best drugs to use. Doctors and patients should be more cautious and deliberative in using these drugs," she added.

The anticonvulsants are also known as anti-epileptics. They were designed -- and are approved by the Food and Drug Administration -- primarily to treat people who have various kinds of seizure disorders, including seizures or convulsions caused by epilepsy, strokes, and brain tumors. Several -- phenytoin (Dilantin), carbamazepine (Carbatrol, Tegretol,), ethotoin (Peganone), and valproic acid/divalproex (Depakene/Depakote) -- have been on the market since the 1950s. But a "second generation" of anticonvulsants was developed in the 1990s. These include gabapentin (Neurontin), lamotrigine (Lamictal), pregabalin (Lyrica) and topiramate (Topamax).

Both the old and new anticonvulsants -- but especially the new ones -- gained traction through the 1990s in treating pain and mental disorders. They all affect the central nervous system. In particular, the drugs are now prescribed often to treat nerve pain, or neuralgia, caused by damage or trauma to the nerves or parts of the nervous system. Nerve pain occurs in many people who have diabetes, for example, which damages nerves and blood vessels. Cancer can also cause nerve pain, as can chemotherapy to treat cancer. Some infections can also cause nerve pain, including HIV. And shingles is a form of intense nerve pain caused by the herpes zoster virus -- affecting over a million people each year.

The report notes that the FDA has now approved several anticonvulsants to treat conditions other than seizures. Namely, divalproex, lamotrigine (Lamictal), and carbamazepine have been approved to treat the manic phases of bipolar disorder; carbamazepine, gabapentin (Neurontin), and pregabalin (Lyrica) have been approved to treat various forms of nerve pain; and pregabalin (Lyrica) was just recently (in June 2007) approved to treat fibromyalgia -- an often chronic condition characterized by muscle pain or soreness, joint tenderness or pain, fatigue, and a chronic, low-grade flu-like feeling.

The report presents evidence supporting those uses, but also cautions that other treatments may sometimes work better or be a better initial choice for some patients. In addition, it presents detailed information on the adverse side effects of the drugs, noting in particular that the newer drugs pose the same level of risk (albeit different risks) as the older drugs.

The report presents detailed cost information on the drugs as well, noting that the newer anticonvulsants can be quite expensive ($300 a month and up), and are generally more costly than the older drugs. However, some of the newer drugs (most notably gabapentin) are now available as lower-cost generics, too.

Taking cost, dosing convenience, and the evidence for effectiveness and adverse effects into consideration, the report chooses the following drugs as Best Buys:

-- Generic carbamazepine -- for treating the mania phase of bipolar disorder or trigeminal neuralgia, a type of nerve pain that affects facial nerves

-- Generic valproic acid -- for treating the mania phase of bipolar disorder

-- Lamotrigine (Lamictal) -- for treating both the mania and depressive phases of bipolar disorder

-- Generic gabapentin -- for treating the nerve pain associated with diabetes or herpes zoster infection (shingles)

-- Pregabalin (Lyrica) -- for treating the nerve pain associated with diabetes or herpes zoster infection (shingles)

The anticonvulsant report is the 19th in a series helping consumers find effective and safe medicines that give them the most value for their health-care dollar. Other reports compare medicines to treat depression, high blood pressure, diabetes, heartburn, high cholesterol, heart disease, asthma, allergies, and overactive bladder.

Consumer Reports Best Buy Drugs(TM) combines a review of the scientific evidence on the effectiveness and safety of medicines with pricing information. Every report is peer-reviewed by medical experts. The project is independently administered by Consumers Union and Consumer Reports with support from the Engelberg Foundation, a private philanthropy, and the National Library of Medicine.


'/>"/>
SOURCE Consumer Reports Best Buy Drugs
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Paracetamol May Cause Live Damage Warns Consumer Education and Research Centre
2. Iodex goes to SmithKline Beecham consumer Healthcare
3. Consumer group seeks Sibutramine ban
4. Identifying What Consumers Look For On Food Stuff Labels
5. Consumers Becoming More Health Conscious Than Calorie Conscious
6. With More Appearance Conscious Consumers The Need For Slimming Products Is Rapidly Rising
7. Consumers of soft drinks to be more alert
8. Consumers Worried About Trans-Fats The Most
9. New Plastic Surgery Unit Set Up In Kolkata To Meet Ever-Increasing Consumer Demand
10. Consumer Court Dismisses Rs 143 Crore Negligence Claim
11. Apex Consumer Court Rejects Rs 143 Cr Medical Negligence Claim
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Maryland (PRWEB) , ... December 06, 2016 , ... ... announced the launch of a Kickstarter crowd funding campaign ( http://kck.st/2g3a1so ) for ... health active alerts and even taking an EKG from the watch while sharing ...
(Date:12/6/2016)... ... December 06, 2016 , ... Specialty ... newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol for Great ... understand the scope of their EHS regulatory obligations and rapidly collect, share, archive, ...
(Date:12/5/2016)... ... ... What: Shriners Hospitals for Children, with the help of Dimension Data, will bring ... monitor and web-enabled camera. Santa visits with children through Dimension Data’s program to connect ... is where the video connection to the North Pole will stream. Much like children ...
(Date:12/5/2016)... ... December 05, 2016 , ... SyncDog, Inc., the leading ... magazine, a leading online tech news platform connecting technology innovators with news, experience, ... explores the state of enterprise mobility security today, and how the SyncDog SentinelSecure™ ...
(Date:12/5/2016)... ... December 05, 2016 , ... Progressive Laboratories™ is ... and glutathione to enhance production of nitric oxide (NO). , NitroGenesis Pro™ is ... produce NO twice as effectively and sustains NO blood levels twice as long ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... GAINESVILLE and BOCA RATON, ... The Florida Institute for the Commercialization of Public ... it has finalized a funding agreement SegAna, LLC, ... technology developed at University of Central Florida. The ... publicly-funded research, and bridges early funding gaps for ...
(Date:12/5/2016)... PUNE, India , December 5, 2016 ... Market by Treatment modalities (Chondrocyte Transplantation, Growth Factor Technology, Tissue Scaffolds, ... 2021" published by MarketsandMarkets, the market is projected to reach USD ... at a CAGR of 13.5% during the forecast period of 2016 ... ...
(Date:12/5/2016)... , Dec. 5, 2016   BIOTRONIK today ... study. The study evaluates the safety and feasibility of ... an office setting. BioMonitor 2 is an ... that is placed underneath a patient,s skin to help ... (fainting). Atrial fibrillation is a leading cause of stroke ...
Breaking Medicine Technology: